Figure 6. Methyl-indole isomers exhibit differential capacity to mediate AHR activity.
(A) HepG2 (40/6) cells were treated as indicated for 4 h; cells were lysed, and luciferase activity was measured. (B) Expression of AHR-responsive CYP1A1 and CYP1B1 within Caco2 cells was determined through qPCR analysis following 4 h of treatment with vehicle, indole (IND), 3-methyl indole (3-MI), 2-methyl indole (2-MI), or 1-methyl indole (1-MI) at a concentration of 20 μM. (C) The mean CYP1A1 enzymatic activity was measured in Caco2 cells following 12 h treatment with DMSO, TCDD (10 nM), or indole/methyl indole isomers (100 μM) and 3 h incubation with luciferin-CEE reagent. (D) Synergistic IL6 expression within Caco2 cells was determined by qPCR following 4 h treatment with vehicle, TCDD (10 nM), or indole/methyl indole isomers (20 μM) with or without the addition of IL1B (10 ng/mL). IL6 secretion by Caco2 cells was determined by ELISA following 24 h treatment with vehicle, TCDD (10 nM) or indole/ methyl indole isomers (100 μM) with or without the addition of IL1B (10 ng/mL). (E) In vitro translated AHR/ARNT gel shift assay displaying treatment capacity to transform human AHR to AHR/ARNT/DNA complex.